Premium
Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens
Author(s) -
Horton John,
Elson Paul,
Gordon Phillip,
Hahn Richard,
Creech Richard
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19820615)49:12<2441::aid-cncr2820491203>3.0.co;2-q
Subject(s) - medicine , megestrol , fluorouracil , doxorubicin , chemotherapy , megestrol acetate , oncology , cyclophosphamide , combination chemotherapy , toxicity , endometrial cancer , surgery , cancer
In patients with advanced uterine corpus carcinoma treated with the combination chemotherapy of megestrol, cyclophosphamide, and doxorubicin (MCA) or with this combination and 5‐fluorouracil (MCAF), the overall response rate was 22%. There was no significant difference in response rates between the two regimens. There is some indication that survival was longer in ambulatory patients who were treated with MCA, but this combination produced more hematologic toxicity than MCAF. Patients unsuitable for treatment with doxorubicin received megestrol, 1‐phenylalanine mustard, and 5‐fluorouracil (MLF), which produced objective responses in 2 of 12 patients.